{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:35:31Z","timestamp":1791484531836,"version":"4.3.4"},"reference-count":170,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,5,22]],"date-time":"2021-05-22T00:00:00Z","timestamp":1621641600000},"content-version":"vor","delay-in-days":294,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.imlet.2020.04.012","type":"journal-article","created":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T23:05:44Z","timestamp":1589151944000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Immune mechanisms involved in sickle cell disease pathogenesis: current knowledge and perspectives"],"prefix":"10.1016","volume":"224","author":[{"given":"J\u00falia Teixeira Cottas","family":"de Azevedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelen Cristina Ribeiro","family":"Malmegrim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9757","key":"10.1016\/j.imlet.2020.04.012_bib0005","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(10)61029-X","article-title":"Sickle-cell disease","volume":"376","author":"Rees","year":"2010","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.imlet.2020.04.012_bib0010","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1542\/pir.33.5.195","article-title":"Sickle cell disease","volume":"33","author":"McCavit","year":"2012","journal-title":"Pediatr Rev"},{"issue":"16","key":"10.1016\/j.imlet.2020.04.012_bib0015","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1021\/jm200531f","article-title":"Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms","volume":"54","author":"dos Santos","year":"2011","journal-title":"J Med Chem"},{"issue":"31-32","key":"10.1016\/j.imlet.2020.04.012_bib0020","first-page":"532","article-title":"Hemoglobinopathies: clinical manifestations, diagnosis, and treatment","volume":"108","author":"Kohne","year":"2011","journal-title":"Dtsch Arztebl Int"},{"issue":"7","key":"10.1016\/j.imlet.2020.04.012_bib0025","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med"},{"issue":"7526","key":"10.1016\/j.imlet.2020.04.012_bib0030","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1038\/515S2a","article-title":"Epidemiology: a moving target","volume":"515","author":"Pleasants","year":"2014","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.imlet.2020.04.012_bib0035","doi-asserted-by":"crossref","first-page":"e2120","DOI":"10.1371\/journal.pntd.0002120","article-title":"Is sickle cell anemia a neglected tropical disease?","volume":"7","author":"Ware","year":"2013","journal-title":"PLoS Negl Trop Dis"},{"issue":"17","key":"10.1016\/j.imlet.2020.04.012_bib0040","doi-asserted-by":"crossref","first-page":"7583","DOI":"10.1021\/jm300602n","article-title":"Design, synthesis, and pharmacological evaluation of novel hybrid compounds to treat sickle cell disease symptoms. part II: furoxan derivatives","volume":"55","author":"Dos Santos","year":"2012","journal-title":"J Med Chem"},{"key":"10.1016\/j.imlet.2020.04.012_bib0045","first-page":"207","article-title":"Fisiopatologia das doen\u00e7as falciformes: da muta\u00e7\u00e3o gen\u00e9tica \u00e0 insufici\u00eancia dem\u00faltiplos \u00f3rg\u00e3os","author":"Zago","year":"2007","journal-title":"Rev. bras. hematol. hemoter."},{"issue":"9442","key":"10.1016\/j.imlet.2020.04.012_bib0050","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1016\/S0140-6736(04)17192-4","article-title":"Sickle-cell disease","volume":"364","author":"Stuart","year":"2004","journal-title":"Lancet"},{"issue":"9778","key":"10.1016\/j.imlet.2020.04.012_bib0055","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG)","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.imlet.2020.04.012_bib0060","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1111\/bjh.12323","article-title":"The effect of hydroxcarbamide therapy on survival of children with sickle cell disease","volume":"161","author":"Lobo","year":"2013","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.imlet.2020.04.012_bib0065","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.crvi.2012.09.006","article-title":"Hydroxycarbamide: clinical aspects","volume":"336","author":"Ware","year":"2013","journal-title":"C R Biol"},{"issue":"22","key":"10.1016\/j.imlet.2020.04.012_bib0070","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1182\/blood-2012-03-419879","article-title":"Impact of hydroxyurea on clinical events in the BABY HUG trial","volume":"120","author":"Thornburg","year":"2012","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.imlet.2020.04.012_bib0075","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1182\/blood.V79.10.2555.2555","article-title":"Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia","volume":"79","author":"Charache","year":"1992","journal-title":"Blood"},{"issue":"20","key":"10.1016\/j.imlet.2020.04.012_bib0080","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJM199505183322001","article-title":"Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia","volume":"332","author":"Charache","year":"1995","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0085","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1182\/blood-2004-01-0322","article-title":"Mortality in sickle cell patients on hydroxyurea therapy","volume":"105","author":"Bakanay","year":"2005","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.imlet.2020.04.012_bib0090","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/MOH.0b013e32834521dd","article-title":"Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?","volume":"18","author":"McGann","year":"2011","journal-title":"Curr Opin Hematol"},{"issue":"3","key":"10.1016\/j.imlet.2020.04.012_bib0095","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.hoc.2016.01.011","article-title":"Management of Patients with Sickle Cell Disease Using Transfusion Therapy: Guidelines and Complications","volume":"30","author":"Chou","year":"2016","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0100","doi-asserted-by":"crossref","first-page":"e2","DOI":"10.1016\/j.ijid.2009.03.010","article-title":"Infection in sickle cell disease: a review","volume":"14","author":"Booth","year":"2010","journal-title":"Int J Infect Dis"},{"issue":"6","key":"10.1016\/j.imlet.2020.04.012_bib0105","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1182\/blood-2013-03-489112","article-title":"Outcome of patients with hemoglobinopathies given either cord blood or bone marrow transplantation from an HLA-identical sibling","volume":"122","author":"Locatelli","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.bmt.1701291","article-title":"Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium","volume":"22","author":"Vermylen","year":"1998","journal-title":"Bone Marrow Transplant"},{"issue":"5","key":"10.1016\/j.imlet.2020.04.012_bib0115","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1365-2141.2007.06592.x","article-title":"Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research","volume":"137","author":"Panepinto","year":"2007","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.imlet.2020.04.012_bib0120","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1056\/NEJM199608083350601","article-title":"Bone marrow transplantation for sickle cell disease","volume":"335","author":"Walters","year":"1996","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0125","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype","volume":"312","author":"Hsieh","year":"2014","journal-title":"Jama"},{"issue":"11","key":"10.1016\/j.imlet.2020.04.012_bib0130","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2020.04.012_bib0135","first-page":"229","article-title":"Hematopoietic stem cell transplantation in sickle cell disease: patient selection and special considerations","volume":"6","author":"Bhatia","year":"2015","journal-title":"J Blood Med"},{"issue":"5","key":"10.1016\/j.imlet.2020.04.012_bib0140","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s41591-019-0401-y","article-title":"Highly efficient therapeutic gene editing of human hematopoietic stem cells","volume":"25","author":"Wu","year":"2019","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.imlet.2020.04.012_bib0145","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene Therapy in a Patient with Sickle Cell Disease","volume":"376","author":"Ribeil","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.imlet.2020.04.012_bib0150","first-page":"532","article-title":"Pathophysiological insights in sickle cell disease","volume":"134","author":"Odi\u00e8vre","year":"2011","journal-title":"Indian J Med Res"},{"issue":"4","key":"10.1016\/j.imlet.2020.04.012_bib0155","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1172\/JCI30920","article-title":"Sickle cell disease: old discoveries, new concepts, and future promise","volume":"117","author":"Frenette","year":"2007","journal-title":"J Clin Invest"},{"issue":"16","key":"10.1016\/j.imlet.2020.04.012_bib0160","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1056\/NEJMra1510865","article-title":"Sickle Cell Disease","volume":"376","author":"Piel","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.imlet.2020.04.012_bib0165","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/ejh.13212","article-title":"Insight into the complex pathophysiology of sickle cell anaemia and possible treatment","volume":"102","author":"Piccin","year":"2019","journal-title":"Eur J Haematol"},{"issue":"7","key":"10.1016\/j.imlet.2020.04.012_bib0170","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1182\/blood-2003-03-0693","article-title":"Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes","volume":"102","author":"Shet","year":"2003","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.imlet.2020.04.012_bib0175","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/bjh.14476","article-title":"Exacerbation of oxidative stress during sickle vaso-occlusive crisis is associated with decreased anti-band 3 autoantibodies rate and increased red blood cell-derived microparticle level: a prospective study","volume":"176","author":"Hierso","year":"2017","journal-title":"Br J Haematol"},{"issue":"24","key":"10.1016\/j.imlet.2020.04.012_bib0180","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1182\/blood-2014-07-589283","article-title":"Circulating cell membrane microparticles transfer heme to endothelial cells and trigger vasoocclusions in sickle cell disease","volume":"125","author":"Camus","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2020.04.012_bib0185","doi-asserted-by":"crossref","first-page":"28414","DOI":"10.3402\/jev.v4.28414","article-title":"Circulating microparticles, protein C, free protein S and endothelial vascular markers in children with sickle cell anaemia","volume":"4","author":"Piccin","year":"2015","journal-title":"J Extracell Vesicles"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0190","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood-2003-08-2760","article-title":"Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease","volume":"104","author":"Jison","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2020.04.012_bib0195","doi-asserted-by":"crossref","first-page":"17822","DOI":"10.1038\/srep17822","article-title":"Role of innate immunity-triggered pathways in the pathogenesis of Sickle Cell Disease: a meta-analysis of gene expression studies","volume":"5","author":"Hounkpe","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.imlet.2020.04.012_bib0200","doi-asserted-by":"crossref","DOI":"10.1177\/1535370216636726","article-title":"Genetic basis of heterogeneity and severity in sickle cell disease","author":"Habara","year":"2016","journal-title":"Exp Biol Med (Maywood)"},{"issue":"24","key":"10.1016\/j.imlet.2020.04.012_bib0205","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2013-10-529982","article-title":"Heme-induced neutrophil extracellular traps contribute to the pathogenesis of sickle cell disease","volume":"123","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2020.04.012_bib0210","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood-2015-12-674606","article-title":"Sickle cell disease: challenges and progress","author":"Parise","year":"2016","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.imlet.2020.04.012_bib0215","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1182\/blood-2015-09-618538","article-title":"Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology","volume":"127","author":"Zhang","year":"2016","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.imlet.2020.04.012_bib0220","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1002\/ajh.22167","article-title":"Immune regulation in chronically transfused allo-antibody responder and nonresponder patients with sickle cell disease and beta-thalassemia major","volume":"86","author":"Bao","year":"2011","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.imlet.2020.04.012_bib0225","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1002\/ajh.23488","article-title":"Regulatory B-cell compartment in transfused alloimmunized and non-alloimmunized patients with sickle cell disease","volume":"88","author":"Bao","year":"2013","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.imlet.2020.04.012_bib0230","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1002\/ajh.23629","article-title":"Partial dysfunction of Treg activation in sickle cell disease","volume":"89","author":"Vingert","year":"2014","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.imlet.2020.04.012_bib0235","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/bjh.13326","article-title":"Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy","volume":"169","author":"Nickel","year":"2015","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0240","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/bjh.12950","article-title":"The spleen and sickle cell disease: the sick(led) spleen","volume":"166","author":"Brousse","year":"2014","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.imlet.2020.04.012_bib0245","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.it.2018.02.007","article-title":"Origin and Immunological Functions of Spleen Stromal Cells","volume":"39","author":"Golub","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1016\/j.imlet.2020.04.012_bib0250","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0074-7696(08)62453-5","article-title":"Cells in the marginal zone of the spleen","volume":"132","author":"Kraal","year":"1992","journal-title":"Int Rev Cytol"},{"issue":"12","key":"10.1016\/j.imlet.2020.04.012_bib0255","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1182\/blood-2004-01-0346","article-title":"Human blood IgM \"memory\" B cells are circulating splenic marginal zone B cells harboring a prediversified immunoglobulin repertoire","volume":"104","author":"Weller","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2020.04.012_bib0260","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3389\/fimmu.2011.00063","article-title":"Marginal zone B-cells, a gatekeeper of innate immunity","volume":"2","author":"Zouali","year":"2011","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.imlet.2020.04.012_bib0265","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1016\/j.humpath.2011.08.011","article-title":"Composition and significance of splenic Gamna-Gandy bodies in sickle cell anemia","volume":"43","author":"Piccin","year":"2012","journal-title":"Hum Pathol"},{"issue":"9","key":"10.1016\/j.imlet.2020.04.012_bib0270","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1182\/blood-2010-04-278747","article-title":"Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial","volume":"117","author":"Rogers","year":"2011","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0275","article-title":"Bacterial Infections Following Splenectomy for Malignant and Nonmalignant Hematologic Diseases","volume":"7","author":"Leone","year":"2015","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"10.1016\/j.imlet.2020.04.012_bib0280","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1111\/j.1365-2141.2008.07564.x","article-title":"Splenectomy in sickle cell anaemia: a cause of further crises?","author":"Piccin","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.imlet.2020.04.012_bib0285","doi-asserted-by":"crossref","DOI":"10.1016\/j.jped.2015.01.002","article-title":"Newborn screening for sickle cell disease: necessary but not sufficient","author":"Wang","year":"2015","journal-title":"J Pediatr (Rio J)"},{"key":"10.1016\/j.imlet.2020.04.012_bib0290","article-title":"Characterization of mortality in children with sickle cell disease diagnosed through the Newborn Screening Program","author":"Sabarense","year":"2014","journal-title":"J Pediatr (Rio J)"},{"issue":"10","key":"10.1016\/j.imlet.2020.04.012_bib0295","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/j.humimm.2007.08.260","article-title":"HLA-E*0101 allele in homozygous state favors severe bacterial infections in sickle cell anemia","volume":"68","author":"Tamouza","year":"2007","journal-title":"Hum Immunol"},{"issue":"7","key":"10.1016\/j.imlet.2020.04.012_bib0300","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1699-0463.1999.tb01463.x","article-title":"Complement haemolytic activity, circulating immune complexes and the morbidity of sickle cell anaemia","volume":"107","author":"Anyaegbu","year":"1999","journal-title":"Apmis"},{"issue":"5","key":"10.1016\/j.imlet.2020.04.012_bib0305","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1136\/adc.57.5.343","article-title":"Defective yeast opsonisation and functional deficiency of complement in sickle cell disease","volume":"57","author":"Larcher","year":"1982","journal-title":"Arch Dis Child"},{"issue":"16","key":"10.1016\/j.imlet.2020.04.012_bib0310","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJM197304192881601","article-title":"An abnormality of the alternate pathway of complement activation in sickle-cell disease","volume":"288","author":"Johnston","year":"1973","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0315","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/0090-1229(89)90098-6","article-title":"Immunological studies in sickle cell disease: comparison of homozygote mild and severe variants","volume":"53","author":"Cetiner","year":"1989","journal-title":"Clin Immunol Immunopathol"},{"issue":"6006","key":"10.1016\/j.imlet.2020.04.012_bib0320","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1136\/bmj.1.6006.367","article-title":"Deficiency of factor B of the complement system in sickle cell anaemia","volume":"1","author":"Wilson","year":"1976","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0325","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1172\/JCI112824","article-title":"Direct evidence that decreased serum opsonization of Streptococcus pneumoniae via the alternative complement pathway in sickle cell disease is related to antibody deficiency","volume":"79","author":"Bjornson","year":"1987","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0330","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.transci.2016.04.008","article-title":"The role of complement activation in thrombosis and hemolytic anemias","volume":"54","author":"Chapin","year":"2016","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.imlet.2020.04.012_bib0335","doi-asserted-by":"crossref","first-page":"e481","DOI":"10.3324\/haematol.2017.174201","article-title":"In vitro evidence of complement activation in patients with sickle cell disease","author":"Gavriilaki","year":"2017","journal-title":"Haematologica, Italy"},{"key":"10.1016\/j.imlet.2020.04.012_bib0340","doi-asserted-by":"crossref","DOI":"10.1002\/ajh.25742","article-title":"Complement activation in sickle cell disease: dependence on cell density, hemolysis and modulation by hydroxyurea therapy","author":"Roumenina","year":"2020","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.imlet.2020.04.012_bib0345","doi-asserted-by":"crossref","first-page":"919","DOI":"10.3324\/haematol.2018.198622","article-title":"Factor H interferes with the adhesion of sickle red cells to vascular endothelium: a novel disease-modulating molecule","volume":"104","author":"Lombardi","year":"2019","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.imlet.2020.04.012_bib0350","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1159\/000205060","article-title":"Antinuclear antibodies in sickle cell disease","volume":"84","author":"Baethge","year":"1990","journal-title":"Acta Haematol"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0355","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3899\/jrheum.100667","article-title":"High titers of autoantibodies in patients with sickle-cell disease","volume":"38","author":"Toly-Ndour","year":"2011","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0360","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s12969-017-0221-x","article-title":"Coexistent sickle-cell anemia and autoimmune disease in eight children: pitfalls and challenges","volume":"16","author":"Li-Thiao-Te","year":"2018","journal-title":"Pediatr Rheumatol Online J"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0365","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.rbr.2013.05.005","article-title":"[Coexisting systemic lupus erythematosus and sickle cell disease: case report and literature review]","volume":"55","author":"Robazzi","year":"2015","journal-title":"Rev Bras Reumatol"},{"key":"10.1016\/j.imlet.2020.04.012_bib0370","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/1752-1947-6-366","article-title":"Systemic lupus erythematosus associated with sickle-cell disease: a case report and literature review","volume":"6","author":"Maamar","year":"2012","journal-title":"J Med Case Rep"},{"issue":"4","key":"10.1016\/j.imlet.2020.04.012_bib0375","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1111\/j.1399-0039.2009.01331.x","article-title":"HLA-G polymorphism influences the susceptibility to HCV infection in sickle cell disease patients","volume":"74","author":"Cordero","year":"2009","journal-title":"Tissue Antigens"},{"issue":"3","key":"10.1016\/j.imlet.2020.04.012_bib0380","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0198-8859(01)00378-0","article-title":"Infectious complications in sickle cell disease are influenced by HLA class II alleles","volume":"63","author":"Tamouza","year":"2002","journal-title":"Hum Immunol"},{"issue":"6","key":"10.1016\/j.imlet.2020.04.012_bib0385","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0022-3476(96)70334-7","article-title":"Relationship between Fc receptor IIA polymorphism and infection in children with sickle cell disease","volume":"128","author":"Norris","year":"1996","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.imlet.2020.04.012_bib0390","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/sj.ejhg.5200360","article-title":"Genetic polymorphism of the mannose-binding protein gene in children with sickle cell disease: identification of three new variant alleles and relationship to infections","volume":"7","author":"Neonato","year":"1999","journal-title":"Eur J Hum Genet"},{"issue":"5","key":"10.1016\/j.imlet.2020.04.012_bib0395","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1086\/506356","article-title":"Association of polymorphisms of IGF1R and genes in the transforming growth factor- beta \/bone morphogenetic protein pathway with bacteremia in sickle cell anemia","volume":"43","author":"Adewoye","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.imlet.2020.04.012_bib0400","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1086\/521200","article-title":"Allele-specific targeting of microRNAs to HLA-G and risk of asthma","volume":"81","author":"Tan","year":"2007","journal-title":"Am J Hum Genet"},{"issue":"10","key":"10.1016\/j.imlet.2020.04.012_bib0405","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0071742","article-title":"Polymorphic Sites at the 3\u2019 Untranslated Region of the HLA-G Gene Are Associated with Differential hla-g Soluble Levels in the Brazilian and French Population","volume":"8","author":"Martelli-Palomino","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.imlet.2020.04.012_bib0410","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1177\/039463200601900213","article-title":"Hierarchy of baby-linked immunogenetic risk factors in the vertical transmission of hepatitis C virus","author":"Martinetti","year":"2006","journal-title":"Int J Immunopathol Pharmacol, Italy"},{"issue":"3","key":"10.1016\/j.imlet.2020.04.012_bib0415","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.bcmd.2014.12.004","article-title":"Interleukin-1beta and interleukin-6 gene polymorphisms are associated with manifestations of sickle cell anemia","volume":"54","author":"Vicari","year":"2015","journal-title":"Blood Cells Mol Dis"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0420","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/hh1401.093314","article-title":"Cardiac-specific expression of heme oxygenase-1 protects against ischemia and reperfusion injury in transgenic mice","volume":"89","author":"Yet","year":"2001","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.imlet.2020.04.012_bib0425","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1038\/nm0302-240","article-title":"Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice","volume":"8","author":"Lee","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.imlet.2020.04.012_bib0430","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.cyto.2016.03.016","article-title":"Sickle red cells as danger signals on proinflammatory gene expression, leukotriene B4 and interleukin-1 beta production in peripheral blood mononuclear cell","volume":"83","author":"Pitanga","year":"2016","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.imlet.2020.04.012_bib0435","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0199461","article-title":"A common molecular signature of patients with sickle cell disease revealed by microarray meta-analysis and a genome-wide association study","volume":"13","author":"Ben Hamda","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.imlet.2020.04.012_bib0440","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1755-8794-5-28","article-title":"A systematic comparison and evaluation of high density exon arrays and RNA-seq technology used to unravel the peripheral blood transcriptome of sickle cell disease","volume":"5","author":"Raghavachari","year":"2012","journal-title":"BMC Med Genomics"},{"issue":"7","key":"10.1016\/j.imlet.2020.04.012_bib0445","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.3324\/haematol.2018.187815","article-title":"Proteomic analysis of plasma from children with sickle cell anemia and silent cerebral infarction","volume":"103","author":"Tewari","year":"2018","journal-title":"Haematologica"},{"issue":"22","key":"10.1016\/j.imlet.2020.04.012_bib0450","doi-asserted-by":"crossref","first-page":"3009","DOI":"10.1182\/blood-2016-11-752279","article-title":"Association of circulating transcriptomic profiles with mortality in sickle cell disease","volume":"129","author":"Desai","year":"2017","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.imlet.2020.04.012_bib0455","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality in sickle cell disease. Life expectancy and risk factors for early death","volume":"330","author":"Platt","year":"1994","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0460","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.V84.2.643.643","article-title":"The acute chest syndrome in sickle cell disease: incidence and risk factors. The Cooperative Study of Sickle Cell Disease","volume":"84","author":"Castro","year":"1994","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0465","first-page":"288","article-title":"Cerebrovascular accidents in sickle cell disease: rates and risk factors","volume":"91","author":"Ohene-Frempong","year":"1998","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.imlet.2020.04.012_bib0470","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1542\/peds.103.3.640","article-title":"Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. The Cooperative Study of Sickle Cell Disease","volume":"103","author":"Kinney","year":"1999","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.imlet.2020.04.012_bib0475","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1600-0609.1998.tb01036.x","article-title":"Peripheral blood neutrophil count and candidacidal activity correlate with the clinical severity of sickle cell anaemia (SCA)","volume":"60","author":"Anyaegbu","year":"1998","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.imlet.2020.04.012_bib0480","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.3324\/haematol.2015.128777","article-title":"Impairment of neutrophil oxidative burst in children with sickle cell disease is associated with heme oxygenase-1","volume":"100","author":"Evans","year":"2015","journal-title":"Haematologica"},{"issue":"3","key":"10.1016\/j.imlet.2020.04.012_bib0485","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood-2013-04-495887","article-title":"Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease","volume":"123","author":"Belcher","year":"2014","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.imlet.2020.04.012_bib0490","doi-asserted-by":"crossref","first-page":"20221","DOI":"10.1074\/jbc.M610737200","article-title":"Characterization of heme as activator of Toll-like receptor 4","volume":"282","author":"Figueiredo","year":"2007","journal-title":"J Biol Chem"},{"issue":"12","key":"10.1016\/j.imlet.2020.04.012_bib0495","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/ni.3590","article-title":"Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions","volume":"17","author":"Martins","year":"2016","journal-title":"Nat Immunol"},{"issue":"6","key":"10.1016\/j.imlet.2020.04.012_bib0500","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1097\/MAJ.0000000000000325","article-title":"Mast cell activation syndrome as a significant comorbidity in sickle cell disease","volume":"348","author":"Afrin","year":"2014","journal-title":"Am J Med Sci"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0505","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/bjh.12628","article-title":"Hydroxycarbamide reduces eosinophil adhesion and degranulation in sickle cell anaemia patients","volume":"164","author":"Pallis","year":"2014","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.imlet.2020.04.012_bib0510","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.exphem.2004.04.010","article-title":"Increased adhesive properties of eosinophils in sickle cell disease","volume":"32","author":"Canalli","year":"2004","journal-title":"Exp Hematol"},{"issue":"3","key":"10.1016\/j.imlet.2020.04.012_bib0515","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1172\/JCI89741","article-title":"Intravascular hemolysis and the pathophysiology of sickle cell disease","volume":"127","author":"Kato","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.imlet.2020.04.012_bib0520","doi-asserted-by":"crossref","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"10.1016\/j.imlet.2020.04.012_bib0525","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/sj.thj.6200310","article-title":"Reduced levels of T-cell subsets CD4+ and CD8+ in homozygous sickle cell anaemia patients with splenic defects","volume":"4","author":"Koffi","year":"2003","journal-title":"Hematol J"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0530","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0165-2478(93)90135-O","article-title":"Reduced levels of CD2+ cells and T-cell subsets in patients with sickle cell anaemia","volume":"37","author":"Kaaba","year":"1993","journal-title":"Immunol Lett"},{"issue":"4","key":"10.1016\/j.imlet.2020.04.012_bib0535","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1128\/CVI.00145-09","article-title":"Pattern of serum cytokine expression and T-cell subsets in sickle cell disease patients in vaso-occlusive crisis","volume":"17","author":"Musa","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"10.1016\/j.imlet.2020.04.012_bib0540","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/eji.201445187","article-title":"Phenotypic differences of CD4(+) T cells in response to red blood cell immunization in transfused sickle cell disease patients","volume":"45","author":"Vingert","year":"2015","journal-title":"Eur J Immunol"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0545","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.cyto.2015.07.016","article-title":"Evaluation of CD4(+)CD25(+)FoxP3(+) T cell populations, IL-10 production, and their correlation with clinical and biochemical parameters in sickle cell anemia patients with leg ulcers","volume":"75","author":"Rego","year":"2015","journal-title":"Cytokine"},{"issue":"3","key":"10.1016\/j.imlet.2020.04.012_bib0550","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/0165-2478(92)90215-A","article-title":"Low number of antibody producing cells in patients with sickle cell anemia","volume":"34","author":"Rautonen","year":"1992","journal-title":"Immunol Lett"},{"issue":"4","key":"10.1016\/j.imlet.2020.04.012_bib0555","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/ajh.2830200413","article-title":"Impaired IgM antibody responses to an influenza virus vaccine in adults with sickle cell anemia","volume":"20","author":"Ballester","year":"1985","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.imlet.2020.04.012_bib0560","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1086\/516781","article-title":"Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine","volume":"44","author":"Halasa","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.imlet.2020.04.012_bib0565","doi-asserted-by":"crossref","DOI":"10.1097\/MPH.0000000000000510","article-title":"Assessing the Immunogenic Response of a Single Center\u2019s Pneumococcal Vaccination Protocol in Sickle Cell Disease","volume":"38","author":"Santoro","year":"2016","journal-title":"J Pediatr Hematol Oncol"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0570","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1542\/peds.2009-1465","article-title":"Burden of influenza-related hospitalizations among children with sickle cell disease","volume":"125","author":"Bundy","year":"2010","journal-title":"Pediatrics"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0575","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJM197907053010106","article-title":"Failure of pneumococcal vaccine in children with sickle-cell disease","volume":"301","author":"Ahonkhai","year":"1979","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0580","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0022-3476(83)80285-6","article-title":"Increased serum opsonic activity and antibody concentration in patients with sickle cell disease after pneumococcal polysaccharide immunization","volume":"102","author":"Chudwin","year":"1983","journal-title":"J Pediatr"},{"issue":"4","key":"10.1016\/j.imlet.2020.04.012_bib0585","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1067\/S0022-3476(03)00331-7","article-title":"Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination","volume":"143","author":"Adamkiewicz","year":"2003","journal-title":"J Pediatr"},{"issue":"6","key":"10.1016\/j.imlet.2020.04.012_bib0590","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1002\/pbc.23259","article-title":"Hospitalization for invasive pneumococcal disease in a national sample of children with sickle cell disease before and after PCV7 licensure","volume":"58","author":"McCavit","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"10.1016\/j.imlet.2020.04.012_bib0595","doi-asserted-by":"crossref","first-page":"432","DOI":"10.3109\/08880018.2013.786157","article-title":"Prevalence of pneumococcal bacteremia in children with sickle cell disease","volume":"30","author":"Patel","year":"2013","journal-title":"Pediatr Hematol Oncol"},{"issue":"3","key":"10.1016\/j.imlet.2020.04.012_bib0600","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1542\/peds.2007-0018","article-title":"Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life","volume":"121","author":"Adamkiewicz","year":"2008","journal-title":"Pediatrics"},{"issue":"12","key":"10.1016\/j.imlet.2020.04.012_bib0605","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1097\/INF.0b013e31814614c6","article-title":"Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease","volume":"26","author":"Reinert","year":"2007","journal-title":"Pediatr Infect Dis J"},{"issue":"3","key":"10.1016\/j.imlet.2020.04.012_bib0610","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1086\/315307","article-title":"Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease","volume":"181","author":"Vernacchio","year":"2000","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.imlet.2020.04.012_bib0615","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/pbc.25502","article-title":"13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study","volume":"62","author":"De Montalembert","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.imlet.2020.04.012_bib0620","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1097\/00043426-200210000-00010","article-title":"Diminished antibody response to hepatitis B immunization in children with sickle cell disease","volume":"24","author":"Hord","year":"2002","journal-title":"J Pediatr Hematol Oncol"},{"issue":"36","key":"10.1016\/j.imlet.2020.04.012_bib0625","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1016\/j.vaccine.2016.06.072","article-title":"Antibody persistence after serogroup C meningococcal conjugate vaccine in children with sickle cell disease","volume":"34","author":"Souza","year":"2016","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0630","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/adc.75.2.159","article-title":"Antibody responses to Haemophilus influenzae type b conjugate vaccine in sickle cell disease","volume":"75","author":"Goldblatt","year":"1996","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.imlet.2020.04.012_bib0635","first-page":"0","article-title":"Regulatory B cells and Allergy: uncovering the link","author":"Mota","year":"2017","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.imlet.2020.04.012_bib0640","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2017.04.014","article-title":"Effector and regulatory B cells in Multiple Sclerosis","author":"Staun-Ram","year":"2017","journal-title":"Clin Immunol"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0645","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/bjh.13567","article-title":"Splenic lymphocyte subtypes in immune thrombocytopenia: increased presence of a subtype of B-regulatory cells","volume":"173","author":"Aslam","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.imlet.2020.04.012_bib0650","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bcmd.2016.01.005","article-title":"Regulatory B cells (CD19(+)CD38(hi)CD24(hi)) in alloimmunized and non-alloimmunized children with beta-thalassemia major","volume":"57","author":"Zahran","year":"2016","journal-title":"Blood Cells Mol Dis"},{"issue":"4","key":"10.1016\/j.imlet.2020.04.012_bib0655","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","article-title":"Regulatory B cells: origin, phenotype, and function","volume":"42","author":"Rosser","year":"2015","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0660","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.clim.2011.03.002","article-title":"Targeting iNKT cells for the treatment of sickle cell disease","volume":"140","author":"Field","year":"2011","journal-title":"Clin Immunol"},{"issue":"17","key":"10.1016\/j.imlet.2020.04.012_bib0665","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1182\/blood-2012-11-465963","article-title":"Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson","volume":"121","author":"Field","year":"2013","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.imlet.2020.04.012_bib0670","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.micinf.2012.05.005","article-title":"Adenosine signaling in normal and sickle erythrocytes and beyond","volume":"14","author":"Zhang","year":"2012","journal-title":"Microbes Infect"},{"issue":"3","key":"10.1016\/j.imlet.2020.04.012_bib0675","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2009-02-205492","article-title":"NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines","volume":"114","author":"Wallace","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0680","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1684\/ecn.2013.0328","article-title":"Altered levels of pro-inflammatory cytokines in sickle cell disease patients during vaso-occlusive crises and the steady state condition","volume":"24","author":"Keikhaei","year":"2013","journal-title":"Eur Cytokine Netw"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0685","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.hemonc.2015.11.002","article-title":"Clinical events and their relation to the tumor necrosis factor-alpha and interleukin-10 genotypes in Sickle-Cell-Anemia patients","volume":"9","author":"Cavalcante","year":"2016","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0690","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.cyto.2011.08.013","article-title":"Increased concentrations of IL-18 and uric acid in sickle cell anemia: contribution of hemolysis, endothelial activation and the inflammasome","volume":"56","author":"Cerqueira","year":"2011","journal-title":"Cytokine"},{"issue":"7","key":"10.1016\/j.imlet.2020.04.012_bib0695","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068929","article-title":"Blood viscosity and the expression of inflammatory and adhesion markers in homozygous sickle cell disease subjects with chronic leg ulcers","volume":"8","author":"Bowers","year":"2013","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.imlet.2020.04.012_bib0700","first-page":"619","article-title":"In vivo production of type 1 cytokines in healthy sickle cell disease patients","volume":"91","author":"Taylor","year":"1999","journal-title":"J Natl Med Assoc"},{"issue":"7","key":"10.1016\/j.imlet.2020.04.012_bib0705","first-page":"611","article-title":"Elevated immunoreactive tumor necrosis factor and interleukin-1 in sickle cell disease","volume":"84","author":"Francis","year":"1992","journal-title":"J Natl Med Assoc"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0710","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.cyto.2009.10.002","article-title":"Plasma interleukin-1beta concentration is associated with stroke in sickle cell disease","volume":"49","author":"Asare","year":"2010","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.imlet.2020.04.012_bib0715","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/ajh.20196","article-title":"Cytokine profile of sickle cell disease in Oman","volume":"77","author":"Pathare","year":"2004","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0720","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cyto.2013.10.009","article-title":"Chronic inflammatory state in sickle cell anemia patients is associated with HBB(*)S haplotype","volume":"65","author":"Bandeira","year":"2014","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0725","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/1076029611420992","article-title":"Biomarkers of inflammation, growth factor, and coagulation activation in patients with sickle cell disease","volume":"18","author":"Qari","year":"2012","journal-title":"Clin Appl Thromb Hemost"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0730","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1111\/j.1600-0609.1998.tb01060.x","article-title":"Acute phase proteins and interleukins in steady state sickle cell disease","volume":"61","author":"Bourantas","year":"1998","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.imlet.2020.04.012_bib0735","doi-asserted-by":"crossref","first-page":"3148","DOI":"10.1182\/blood.V92.9.3148","article-title":"Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis","volume":"92","author":"Michaels","year":"1998","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.imlet.2020.04.012_bib0740","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1182\/blood.V92.7.2551","article-title":"Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis","volume":"92","author":"Graido-Gonzalez","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2020.04.012_bib0745","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.cyto.2016.02.012","article-title":"Plasma levels of TGF-beta1 in homeostasis of the inflammation in sickle cell disease","volume":"80","author":"Torres Lde","year":"2016","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.imlet.2020.04.012_bib0750","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000041049","article-title":"Th1 and Th2 cytokine profiles in sickle cell disease","volume":"103","author":"Raghupathy","year":"2000","journal-title":"Acta Haematol"},{"issue":"11","key":"10.1016\/j.imlet.2020.04.012_bib0755","first-page":"753","article-title":"Type 2 cytokine serum levels in healthy sickle cell disease patients","volume":"89","author":"Taylor","year":"1997","journal-title":"J Natl Med Assoc"},{"issue":"10","key":"10.1016\/j.imlet.2020.04.012_bib0760","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1590\/S0100-879X2001001000011","article-title":"Interleukin 8 as a vaso-occlusive marker in Brazilian patients with sickle cell disease","volume":"34","author":"Goncalves","year":"2001","journal-title":"Braz J Med Biol Res"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0765","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.cyto.2013.11.012","article-title":"Evaluation of Th17 related cytokines associated with clinical and laboratorial parameters in sickle cell anemia patients with leg ulcers","volume":"65","author":"da Silva","year":"2014","journal-title":"Cytokine"},{"issue":"4","key":"10.1016\/j.imlet.2020.04.012_bib0770","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1542\/peds.2014-0571","article-title":"Immunologic effects of hydroxyurea in sickle cell anemia","volume":"134","author":"Lederman","year":"2014","journal-title":"Pediatrics"},{"issue":"2","key":"10.1016\/j.imlet.2020.04.012_bib0775","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1189\/jlb.0708445","article-title":"Altered levels of cytokines and inflammatory mediators in plasma and leukocytes of sickle cell anemia patients and effects of hydroxyurea therapy","volume":"85","author":"Lanaro","year":"2009","journal-title":"J Leukoc Biol"},{"issue":"3","key":"10.1016\/j.imlet.2020.04.012_bib0780","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/blood-2011-11-327361","article-title":"Red blood cell alloimmunization in sickle cell disease: pathophysiology, risk factors, and transfusion management","volume":"120","author":"Yazdanbakhsh","year":"2012","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.imlet.2020.04.012_bib0785","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/ajh.24188","article-title":"Immunophenotypic parameters and RBC alloimmunization in children with sickle cell disease on chronic transfusion","volume":"90","author":"Nickel","year":"2015","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.imlet.2020.04.012_bib0790","doi-asserted-by":"crossref","first-page":"102","DOI":"10.4049\/jimmunol.1400105","article-title":"Hemin controls T cell polarization in sickle cell alloimmunization","volume":"193","author":"Zhong","year":"2014","journal-title":"J Immunol"},{"issue":"11","key":"10.1016\/j.imlet.2020.04.012_bib0795","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3324\/haematol.2015.132738","article-title":"TIGIT-positive circulating follicular helper T cells display robust B-cell help functions: potential role in sickle cell alloimmunization","volume":"100","author":"Godefroy","year":"2015","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.imlet.2020.04.012_bib0800","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3324\/haematol.2016.147181","article-title":"Altered heme-mediated modulation of dendritic cell function in sickle cell alloimmunization","volume":"101","author":"Godefroy","year":"2016","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.imlet.2020.04.012_bib0805","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1002\/pbc.25059","article-title":"Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin","volume":"61","author":"Soni","year":"2014","journal-title":"Pediatr Blood Cancer"},{"issue":"7","key":"10.1016\/j.imlet.2020.04.012_bib0810","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1038\/bmt.2014.84","article-title":"Reduced toxicity, myeloablative conditioning with BU, fludarabine, alemtuzumab and SCT from sibling donors in children with sickle cell disease","volume":"49","author":"Bhatia","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.imlet.2020.04.012_bib0815","doi-asserted-by":"crossref","first-page":"3868","DOI":"10.1172\/JCI87885","article-title":"Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype","volume":"126","author":"Brendel","year":"2016","journal-title":"J Clin Invest"},{"issue":"9","key":"10.1016\/j.imlet.2020.04.012_bib0820","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/nm.4170","article-title":"A genome-editing strategy to treat beta-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition","volume":"22","author":"Traxler","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.imlet.2020.04.012_bib0825","series-title":"Interim Results from a Phase 1\/2 Clinical Study of Lentiglobin Gene Therapy for Severe Sickle Cell Disease","author":"Kanter","year":"2016"},{"key":"10.1016\/j.imlet.2020.04.012_bib0830","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.lfs.2017.03.025","article-title":"Therapeutic strategies in Sickle Cell Anemia: The past present and future","volume":"178","author":"Fernandes","year":"2017","journal-title":"Life Sci"},{"issue":"7","key":"10.1016\/j.imlet.2020.04.012_bib0835","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood-2015-09-618587","article-title":"Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease","volume":"127","author":"Hoban","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.imlet.2020.04.012_bib0840","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.ymthe.2017.03.024","article-title":"Gene Therapy for beta-Hemoglobinopathies","volume":"25","author":"Cavazzana","year":"2017","journal-title":"Mol Ther"},{"issue":"19","key":"10.1016\/j.imlet.2020.04.012_bib0845","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1182\/bloodadvances.2018016725","article-title":"Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients","volume":"2","author":"Esrick","year":"2018","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.imlet.2020.04.012_bib0850","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3324\/haematol.2017.184788","article-title":"Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion","volume":"103","author":"Lagresle-Peyrou","year":"2018","journal-title":"Haematologica"}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016524782030016X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016524782030016X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T07:36:39Z","timestamp":1759044999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016524782030016X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":170,"alternative-id":["S016524782030016X"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2020.04.012","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immune mechanisms involved in sickle cell disease pathogenesis: current knowledge and perspectives","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2020.04.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Federation of Immunological Societies. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}